Citations

Clear

6274 citation(s) found for "To, Andrew".

Pulmonary hypertension due to interstitial lung disease or chronic obstructive pulmonary disease: a patient experience study of symptoms and their impact on quality of life
DuBrock, Hilary M. , Nathan, Steven D. , Mathai, Stephen C. , Classi, Peter, Nelsen, Andrew C. , Olayinka‐Amao, Bimpe, Norcross, Lindsey , Martin, Susan , Martin, Susan A , DuBrock, Hilary M , Mathai, Stephen C , Reeve, Bryce B. , Kolaitis, Nicholas A

Mayo Clinic

Pulmonary Circulation | March 16, 2021 | Volume: 11 | Issue: 2 | Pages: 1-9

10.1177/20458940211005641 | PMID 33868642 Get It

Pulmonary hypertension resulting from chronic lung disease such as chronic obstructive pulmonary disease and interstitial lung disease is categorized by the World Health Organization as Group 3 pulmonary hypertension. To identify the symptoms and impacts of World Health Organization Group 3 pulmonary hypertension and to capture data related to the patient experience of this disease, qualitative research interviews were undertaken with 3 clinical experts and 14 individuals with pulmonary hypertension secondary to chronic obstructive pulmonary disease or interstitial lung disease. Shortness of breath, fatigue, cough, and swelling were the most frequently reported symptoms of pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease, and shortness of breath was further identified as the single most bothersome symptom for most patients (71.4%). Interview participants also described experiencing a number of impacts related to pulmonary hypertension and pulmonary hypertension symptoms, including limitations in the ability to perform activities of daily living and impacts on physical functioning, family life, and social life as well as emotional impacts, which included frustration, depression, anxiety, isolation, and sadness. Results of these qualitative interviews offer an understanding of the patient experience of pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease, including insight into the symptoms and impacts that are most important to patients in this population. As such, these results may help guide priorities in clinical treatment and assist researchers in their selection of patient‐reported outcome measures for clinical trials in patients with pulmonary hypertension due to chronic obstructive pulmonary disease or interstitial lung disease.
Comparison of Nuclear Grade, Necrosis, and Histologic Subtype Between Biopsy and Resection in Pleural Malignant Mesothelioma: An International Multi-Institutional Analysis
Schulte, Jefree J. , Chapel, David B. , Attanoos, Richard , Brčić, Luka , Burn, Juliet, Butnor, Kelly J. , Chang, Nina, Chen, Heather , Đačić, Sanja , Godschachner, Theresa, Hiroshima, Kenzo , Klebe, Sonja , Krausz, Thomas, Litzky, Leslie A., Marchevsky, Alberto M. , Mueller, Jeffrey , Nabeshima, Kazuki , Roden, Anja C. , Rørvig, Sara, Santoni‐Rugiu, Eric , Tazelaar, Henry D. , Walts, Ann E. , Weynand, Birgit , Zaizen, Yoshiaki , Zhang, Yu Zhi , Husain, Aliya N. , Santoni-Rugiu, Eric , Tazelaar, Henry, Zhang, Yu Zhi , Zaizen, Yoshiaki , de Perrot, Marc , Fukuoka, Junya , Galateau-Sallé, Françoise , Nicholson, Andrew G. , Pal, Prodipto , Tazelaar, Henry D. , Tsao, Ming‐Sound

Mayo Clinic

American Journal of Clinical Pathology | March 16, 2021 | Volume: 156 | Issue: 6 | Pages: 989-999

10.1093/ajcp/aqab054 | PMID 33978147 Get It

Abstract Objectives Numerous studies on malignant mesothelioma (MM) highlight the prognostic importance of histologic subtype, nuclear grade, and necrosis. This study compares these parameters in paired biopsy and resection specimens of pleural MM. Methods Histologic subtype, percentage of epithelioid morphology, nuclear grade, and the presence or absence of necrosis were compared in 429 paired biopsies and resection specimens of pleural MM from 19 institutions. Results Histologic subtype was concordant in 81% of cases (κ = 0.58). When compared with resection specimens, epithelioid morphology at biopsy had a positive predictive value (PPV) of 78.9% and a negative predictive value (NPV) of 93.5%; sarcomatoid morphology showed high PPV (92.9%) and NPV (99.3%), and biphasic morphology PPV was 89.7% and NPV was 79.7%. Agreement of the percentage of epithelioid morphology was fair (κ = 0.27). Nuclear grade and necrosis were concordant in 75% (κ = 0.59) and 81% (κ = 0.53) of cases, respectively. Nuclear grade showed moderate (κ = 0.53) and substantial (κ = 0.67) agreement from patients with and without neoadjuvant therapy, respectively, and necrosis showed moderate (κ = 0.47 and κ = 0.60) agreement, respectively, in the same subsets of paired specimens. Conclusions Paired biopsy-resection specimens from pleural MM show overall moderate agreement in pathologic parameters. These findings may help guide postbiopsy management and triage of patients with MM.
AACC Practical Recommendations for Implementing and Interpreting SARS-CoV-2 Emergency Use Authorization and Laboratory-Developed Test Serologic Testing in Clinical Laboratories
Zhang, Y Victoria , Wiencek, Joesph R , Theel, Elitza S. , Babić, Nikolina , Sepiashvili, Lusia, Pecora, Nicole , Slev, Patricia, Cameron, Andrew , Konforte, Danijela , Wiencek, Joesph , Zhang, Y Victoria, Meng, Qing H.

Mayo Clinic

Clinical Chemistry | March 16, 2021 | Volume: 67 | Issue: 9 | Pages: 1188-1200

10.1093/clinchem/hvab051 | PMID 34470034 Get It

Abstract Background The clinical laboratory continues to play a critical role in managing the coronavirus pandemic. Numerous US Food and Drug Administration emergency use authorization (EUA) and laboratory-developed test (LDT) serologic assays have become available. The performance characteristics of these assays and their clinical utility continue to be defined in real time during this pandemic. The AACC convened a panel of experts from clinical chemistry, microbiology, and immunology laboratories; the in vitro diagnostics industry; and regulatory agencies to provide practical recommendations for implementation and interpretation of these serologic tests in clinical laboratories. Content The currently available EUA serologic tests and platforms, information on assay design, antibody classes including neutralizing antibodies, and the humoral immune responses to SARS-CoV-2 are discussed. Verification and validation of EUA and LDT assays are described, along with a quality management approach. Four indications for serologic testing are outlined. Recommendations for result interpretation, reporting comments, and the role of orthogonal testing are also presented. Summary This document aims to provide a comprehensive reference for laboratory professionals and healthcare workers to appropriately implement SARS-CoV-2 serologic assays in the clinical laboratory and to interpret test results during this pandemic. Given the more frequent occurrence of outbreaks associated with either vector-borne or respiratory pathogens, this document will be a useful resource in planning for similar scenarios in the future.
Comparison of In Situ Hybridization, Immunohistochemistry, and Reverse Transcription–Droplet Digital Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Tissue
Roden, Anja C. , Vrana, Julie A. , Koepplin, Justin W. , Hudson, Angela, Norgan, Andrew P. , Jenkinson, Garrett , Yamaoka, Satoko , Monroe, R. J., Szabolcs, Matthias, Majumdar, Ramanath, Moyer, Ann M. , García, Joaquín J. , Kipp, Benjamin R. , Hudson, Angela E, Norgan, Andrew P , Ebihara, Hideki , Monroe, Robert

Mayo Clinic

Archives of Pathology & Laboratory Medicine | March 15, 2021 | Volume: 145 | Issue: 7 | Pages: 785-796

10.5858/arpa.2021-0008-sa | PMID 33720333 Get It

Context.— Small case series have evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection in formalin-fixed, paraffin-embedded tissue using reverse transcription–polymerase chain reaction, immunohistochemistry (IHC), and/or RNA in situ hybridization (RNAish). Objective.— To compare droplet digital polymerase chain reaction, IHC, and RNAish to detect SARS-CoV-2 in formalin-fixed, paraffin-embedded tissue in a large series of lung specimens from coronavirus disease 2019 (COVID-19) patients. Design.— Droplet digital polymerase chain reaction and RNAish used commercially available probes; IHC used clone 1A9. Twenty-six autopsies of COVID-19 patients with formalin-fixed, paraffin-embedded tissue blocks of 62 lung specimens, 22 heart specimens, 2 brain specimens, and 1 liver, and 1 umbilical cord were included. Control cases included 9 autopsy lungs from patients with other infections/inflammation and virus-infected tissue or cell lines. Results.— Droplet digital polymerase chain reaction had the highest sensitivity for SARS-CoV-2 (96%) when compared with IHC (31%) and RNAish (36%). All 3 tests had a specificity of 100%. Agreement between droplet digital polymerase chain reaction and IHC or RNAish was fair (κ = 0.23 and κ = 0.35, respectively). Agreement between IHC and in situ hybridization was substantial (κ = 0.75). Interobserver reliability was almost perfect for IHC (κ = 0.91) and fair to moderate for RNAish (κ = 0.38–0.59). Lung tissues from patients who died earlier after onset of symptoms revealed higher copy numbers by droplet digital polymerase chain reaction (P = .03, Pearson correlation = −0.65) and were more likely to be positive by RNAish (P = .02) than lungs from patients who died later. We identified SARS-CoV-2 in hyaline membranes, in pneumocytes, and rarely in respiratory epithelium. Droplet digital polymerase chain reaction showed low copy numbers in 7 autopsy hearts from ProteoGenex Inc. All other extrapulmonary tissues were negative. Conclusions.— Droplet digital polymerase chain reaction was the most sensitive and highly specific test to identify SARS-CoV-2 in lung specimens from COVID-19 patients.
Microvascular Transposition Without Teflon: A Single Institution's 17-Year Experience Treating Trigeminal Neuralgia
Pines, Andrew R. , Butterfield, Richard , Turcotte, Evelyn L. , García, José Omar de Armas , Lucia, Noel De, Algier, Emily J, Zimmerman, Richard S. , Garcia, Jose O, De Lucia, Noel, Patel, Naresh P.

Mayo Clinic

Operative Neurosurgery | March 14, 2021 | Volume: 20 | Issue: 4 | Pages: 397-405

10.1093/ons/opaa413 | PMID 33432975 Get It

Abstract BACKGROUND Trigeminal neuralgia (TN) refractory to medical management is often treated with microvascular decompression (MVD) involving the intracranial placement of Teflon. The placement of Teflon is an effective treatment, but does apply distributed pressure to the nerve and has been associated with pain recurrence. OBJECTIVE To report the rate of postoperative pain recurrence in TN patients who underwent MVD surgery using a transposition technique with fibrin glue without Teflon. METHODS Patients were eligible for our study if they were diagnosed with TN, did not have multiple sclerosis, and had an offending vessel that was identified and transposed with fibrin glue at our institution. All eligible patients were given a follow-up survey. We used a Kaplan-Meier (KM) model to estimate overall pain recurrence. RESULTS A total of 102 patients met inclusion criteria, of which 85 (83%) responded to our survey. Overall, 76 (89.4%) participants responded as having no pain recurrence. Approximately 1-yr pain-free KM estimates were 94.1% (n = 83), 5-yr pain-free KM estimates were 94.1% (n = 53), and 10-yr pain-free KM estimates were 83.0% (n = 23). CONCLUSION Treatment for TN with an MVD transposition technique using fibrin glue may avoid some cases of pain recurrence. The percentage of patients in our cohort who remained pain free at a maximum of 17 yr follow-up is on the high end of pain-free rates reported by MVD studies using Teflon. These results indicate that a transposition technique that emphasizes removing any compression near the trigeminal nerve root provides long-term pain-free rates for patients with TN.
Abstract S06-03: Outcomes of COVID-19 in patients with cancer: Results of a prospective observational comparison of routine screening strategy versus testing based on clinical suspicion
Abeykoon, Jithma P. , Almquist, Daniel , Andrade-Gonzalez, Xavier , Hickman, Ashley , Sorenson, K, Rakshit, Sagar, Wee, Christopher Eing , Tella, Sri Harsha , Abdallah, Nadine , Uprety, Dipesh , Gangat, Naseema , Thompson, Carrie A. , Leventakos, Konstantinos , Xie, Zhuoer , Saliba, Antoine N. , Majeed, Umair , Wiedmeier, Julia E. , Bezerra, Evandro D. , Kommalapati, Anuhya , Pritchett, Joshua C. , Andrade, Mariza de , Badley, Andrew D. , Hubbard, Joleen M. , Witzig, Thomas E. , McWilliams, Robert R. , Hálfdánarson, Þorvarður R.

Mayo Clinic

Clinical Cancer Research | March 12, 2021 | Volume: 27 | Issue: 6_Supplement | Pages: S06-03-S06-03

10.1158/1557-3265.covid-19-21-s06-03 Get It

Abstract Abstract Importance: The benefit of routine screening for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in patients with cancer before cancer-directed therapies is unclear. Herein, we characterize the outcomes of a cohort of cancer patients diagnosed with Coronavirus Disease 2019 (COVID-19) by routine screening in comparison with those diagnosed based on clinical suspicion or exposure history (non-routine screening). Objective: To describe and compare the outcomes of cancer patients diagnosed with COVID-19 on routine screening vs. non-routine screening at a multi-site tertiary cancer center. To identify risk factors for COVID-19-related hospital admission. Design: A multi-site prospective observational study was conducted between March 18 and July 31, 2020. Setting: Three major and 5 satellite campuses of the Mayo Clinic Cancer Center. Participants: Adult patients diagnosed with active cancer within the past five years and confirmed SARS-CoV-2 infection were included. Primary Outcomes and Measures: Clinical and laboratory data were assessed as independent variables. The primary outcome was COVID-19-related hospital admission. Secondary outcomes included intensive care unit (ICU) admissions and all-cause mortality. Results: Between March 18 and July 31, 2020, 5452 patients underwent routine screening in the outpatient setting, 44 (0.81%) were diagnosed with COVID-19. Routine screening detected additional 19 patients from inpatient and pre-procedural settings; 161 patients were diagnosed with COVID-19 based on non-routine screening. The median age of the entire cohort at diagnosis was 54 years, and 95 patients (42.2%) were female. COVID-19 related-hospitalization rate (17.5% vs. 26.7%, p=0.14), ICU admission (1.6% vs. 5.6%, p=0.19), and mortality (4.8% vs. 3.7%, p=0.72) were not significantly different between routine screening and non-routine screening groups. In the multivariable analysis, age ≥ 60 years (odds ratio: 4.4, p=0.023) and an absolute lymphocyte count ≤1.4 × 109/L (odds ratio: 9.2, p=0.002) were independent predictors of COVID-19-related hospital admission. Conclusions and Relevance: The COVID-19 positivity rate was low based on routine screening. Comparing the outcome with the non-routine screening cohort, there was no significant difference. These results led to an important practice change at our cancer center. We currently follow a testing strategy based on symptoms, exposure, risk factors, and clinical judgment. Citation Format: Zhuoer Xie, Antoine N. Saliba, Jithma Abeykoon, Umair Majeed, Daniel Almquist, Julia Wiedmeier-Nutor, Evandro Bezerra, Xavier Andrade-Gonzalez, Ashley Hickman, Karl Sorenson, Sagar Rakshit, Christopher Wee, Sri Tella, Anuhya Kommalapati, Nadine Abdallah, Joshua Pritchett, Mariza De Andrade, Dipesh Uprety, Andrew Badley, Joleen Hubbard, Naseema Gangat, Carrie A. Thompson, Thomas Witzig, Robert R. McWilliams, Konstantinos Leventakos, Thorvardur R. Halfdanarson. Outcomes of COVID-19 in patients with cancer: Results of a prospective observational comparison of routine screening strategy versus testing based on clinical suspicion [abstract]. In: Proceedings of the AACR Virtual Meeting: COVID-19 and Cancer; 2021 Feb 3-5. Philadelphia (PA): AACR; Clin Cancer Res 2021;27(6_Suppl):Abstract nr S06-03.
User-centered design and development of a trunk control device for persons with spinal cord injury: A pilot study
Looft, John M. , Sjoholm, Robert, Hansen, Andrew H. , Fairhurst, Stuart, Voss, Greg, Dellamano, Clifford A., Egginton, Jason S. , Olney, Christine M. , Goldish, Gary D, Egginton, Jason, Olney, Christine

Mayo Clinic

The Journal of Spinal Cord Medicine | March 12, 2021 | Volume: 45 | Issue: 4 | Pages: 585-594

10.1080/10790268.2020.1863897 | PMID 33705266 Get It

Abnormal vascular physiology in the lower extremities as a risk factor for ischemic stroke and mortality
Bhatt, Shubhang K. , Firth, Christine , Girardo, Marlene , Sykora, Daniel , Abdelmalek, Mina, Fortuin, F. David , Wennberg, Paul W. , Liedl, David , Shamoun, Fadi , Tseng, Andrew S. , Wennberg, Paul, Shamoun, Fadi E.

Mayo Clinic

Journal of Osteopathic Medicine | March 10, 2021 | Volume: 121 | Issue: 5 | Pages: 463-470

10.1515/jom-2020-0290 | PMID 33691353 Get It

Abstract Context Peripheral artery disease (PAD) is highly prevalent in the general population, affecting up to 25% of patients 55 years of age or older. There is a known association with acute ischemic stroke, but limited large cohort studies exist pertaining to the relationship between PAD severity and incident ischemic stroke. Objectives To evaluate the risk of incident ischemic stroke and mortality along the spectrum of low and elevated ankle brachial index (ABI) measurement. Methods We performed a retrospective extraction of ABI data of all adult patients who underwent lower extremity physiology study for any indication from January 1, 1996 to June 30, 2018 in the Mayo Clinic health system. PAD was categorized into severe, moderate, mild, and borderline based on ABI measurements and poorly compressible arteries (PCA). These were compared with normal ABI measurements. Associations of PAD/PCA with new ischemic stroke events and all cause mortality were analyzed. Hazard ratios (HR) were calculated using multivariable Cox proportional regression with 95% confidence intervals. Results A total of 39,834 unique patients were included with a median follow up duration of 4.59 years. All abnormal ABI groups, except borderline PAD, were associated with increased risk of incident ischemic stroke after multivariate regression compared to normal ABI. A severity-dependent association was observed between PAD and ischemic stroke with moderate (HR, 1.22 [95% CI, 1.10–1.35]) and severe (HR, 1.19 [95% CI, 1.02–1.40]) categories conferring similar risk in comparison to normal ABI. Patients with PCA carried the greatest ischemic stroke risk (HR, 1.30 [95% CI, 1.15–1.46]). Similarly, abnormal ABI groups were associated with a significant risk for all cause mortality in a severity-dependent manner, with severe PAD conferring the greatest risk (HR, 3.07 [95% CI, 2.88–3.27]). Conclusions This study adds to the growing body of evidence that both PAD and PCA are independent risk factors for incident ischemic stroke and all cause mortality. The association of PAD severity and PCA with risk of ischemic stroke may help clinicians with risk stratification and determining treatment intensity.
Transplant outcomes using kidneys from high KDPI acute kidney injury donors
Hanna, W. A., Ninan, Jacob, Ryan, Margaret , Das, Devika , Khamash, Hasan , Mathur, Amit K. , Singer, Andrew L., Moss, Adyr A. , Reddy, Kunam S. , Heilman, Raymond L. , Jadlowiec, Caroline , Hanna, Wael A, Ryan, Margaret S, Das, Devika M, Mathur, Amit , Singer, Andrew, Das, Devika , Jadlowiec, Caroline C. , Hanna, Wael A., Smith, Maxwell L.

Mayo Clinic

Clinical Transplantation | March 10, 2021 | Volume: 35 | Issue: 5 | Pages: No page available

10.1111/ctr.14279 | PMID 33690907 Get It

AbstractKidney transplant (KT) outcomes from high kidney donor profile index (KDPI ≥85%) donors with acute kidney injury (AKI) remain underreported. KT from 172 high KDPI Acute Kidney Injury Network (AKIN) stage 0‐1 donors and 76 high KDPI AKIN stage 2‐3 donors from a single center were retrospectively assessed. The AKIN 2‐3 cohort had more delayed graft function (71% vs. 37%, p < .001). At one year, there were no differences in the estimated glomerular filtration rate (44 ± 17 vs. 46 ± 18, p = .42) or fibrosis on protocol biopsy (ci, p = .85). Donor terminal creatinine (p = .59) and length of delayed graft function (p = .39) did not impact one‐year eGFR. There were more primary nonfunction (PNF) events in the high KDPI AKIN 2‐3 group (5.3% vs. 0.6%, p = .02). With a median follow‐up of 3.8 years, one‐year death‐censored graft failure was 3.5% for AKIN 0‐1 and 14.5% for AKIN 2‐3 (HR 2.40, 95% CI 1.24‐4.63, p = .01). Although AKIN stage 2‐3 high KDPI kidneys had comparable one‐year eGFR to AKIN stage 0‐1 high KDPI kidneys, there were more PNF occurrences and one‐year death‐censored graft survival was reduced. Given these findings, additional precautions should be undertaken when assessing and utilizing kidneys from severe AKI high KDPI donors.
Total Nephron Number and Single-Nephron Parameters in Patients with IgA Nephropathy
Marumoto, Hirokazu , D’Agati, Vivette D. , Sasaki, Takaya , Okabayashi, Yusuke , Haruhara, Kotaro , Kanzaki, Go , Koike, Kentaro , Shimizu, Akira , Kawamura, Tetsuya , Yokoo, Takashi , Tsuboi, Nobuo , Rule, Andrew D. , Bertram, John F.

Mayo Clinic

Kidney360 | March 10, 2021 | Volume: 2 | Issue: 5 | Pages: 828-841

10.34067/kid.0006972020 | PMID 35373063 Get It

Key Points This is the first study that estimated total nephron number and related single-nephron parameters in patients with IgA nephropathy. Associations of nephron-level parameters with CKD stage and clinicopathologic findings were cross-sectionally investigated. This study illustrates the feasibility and usefulness of estimating single-nephron dynamics in human GN. Background Single-nephron dynamics in progressive IgA nephropathy (IgAN) have not been studied. We applied novel methodology to explore single-nephron parameters in IgAN. Methods Nonglobally sclerotic glomeruli (NSG) and globally sclerotic glomeruli (GSG) per kidney were estimated using cortical volume assessment via unenhanced computed tomography and biopsy-based stereology. Estimated single-nephron GFR (eSNGFR) and single-nephron urine protein excretion (SNUPE) were calculated by dividing eGFR and UPE by the number of NSG. Associations with CKD stage and clinicopathologic findings were cross-sectionally investigated. Results This study included 245 patients with IgAN (mean age 43 years, 62% male, 45% on renin-angiotensin aldosterone system [RAAS] inhibitors prebiopsy) evaluated at kidney biopsy. CKD stages were 10% CKD1, 43% CKD2, 19% CKD3a, 14% CKD3b, and 14% CKD4–5. With advancing CKD stage, NSG decreased from mean 992,000 to 300,000 per kidney, whereas GSG increased from median 64,000 to 202,000 per kidney. In multivariable models, advancing CKD stage associated with lower numbers of NSG, higher numbers of GSG, and lower numbers of GSG + NSG, indicating potential resorption of sclerosed glomeruli. In contrast to the higher mean glomerular volume and markedly elevated SNUPE in advanced CKD, the eSNGFR was largely unaffected by CKD stage. Lower SNGFR associated with Oxford scores for endocapillary hypercellularity and crescents, whereas higher SNUPE associated with segmental glomerulosclerosis and tubulointerstitial scarring. Conclusions SNUPE emerged as a sensitive biomarker of advancing IgAN. The failure of eSNGFR to increase in response to reduced number of functioning nephrons suggests limited capacity for compensatory hyperfiltration by diseased glomeruli with intrinsic lesions.